NCT04657939View on ClinicalTrials.gov

Targeting Beta-cell Failure in Lean Patients With Type 2 Diabetes

PHASE4CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

December 1, 2020

Primary Completion Date

October 31, 2022

Study Completion Date

October 31, 2022

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Liraglutide

Liraglutide 0.6mg once daily by subcutaneous injection escalated to 1.2mg after 2 weeks.

DRUG

Pioglitazone

Pioglitazone 15mg once daily tablets taken orally escalated to 30mg after 2 weeks then escalated to 45mg after another 2 weeks.

Trial Locations (1)

LS1 3EX

Leeds Teaching Hospitals Trust, Leeds

All Listed Sponsors
lead

University of Leeds

OTHER

NCT04657939 - Targeting Beta-cell Failure in Lean Patients With Type 2 Diabetes | Biotech Hunter | Biotech Hunter